Percutaneous thermal ablation for the treatment of colorectal liver metastases and hepatocellular carcinoma: a comparison of local therapeutic efficacy. (19th May 2017)

• Record Type: Journal Article
• Authors: Liu, Ming; Huang, Guang-liang; Xu, Ming; Pan, Fu-shun; Lu, Ming-de; Zheng, Ke-guo; Kuang, Ming; Xie, Xiao-yan
• Is Part Of: International journal of hyperthermia. Volume 33:Number 4(2017)
• Page Start: 446
• Page End: 453
• Publication Date: 2017-05-19
• Subjects: Colorectal liver metastases -- hepatocellular carcinoma -- thermal ablation -- local efficacy -- comparative study; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2017.1278622
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Aim: This study aimed to compare the local therapeutic efficacy of percutaneous thermal ablation for colorectal liver metastases (CRLM) and hepatocellular carcinoma (HCC). Methods: One hundred sixty-one CRLM nodules in 101 patients and 122 HCC nodules in 97 patients were treated with thermal ablation. Complications and local efficacy were retrospectively compared. Results: Major complications were observed in two (2.0%) patients in the CRLM group and one (1.0%) in the HCC group ( p = 1.000). The complete ablation (CA) rate of lesions ≤ 3 cm was lower in the CRLM group than in the HCC group ( p = 0.018). After a mean follow-up period of 21.1 ± 20.7 months in the CRLM group and 22.1 ± 17.6 months in the HCC group, the local tumour progression (LTP) rate of lesions > 3 cm was higher in the CRLM group than in the HCC group ( p = 0.036). The multivariate analysis revealed that only safety margin (≤ 0.5 cm/> 0.5 cm) was a significant predictor of LTP in both CRLM and HCC. Conclusions: To achieve better local tumour control, thermal ablation should be more aggressive for CRLM than for HCC, especially for large tumours in clinical.